粒细胞和单核细胞吸附疗法可控制伴IL36RN突变的儿童泛发性脓疱型银屑病
本文报告一名IL36RN突变致IL-36受体拮抗剂缺陷(DITRA)的儿科患者,皮损从婴儿期寻常型银屑病演变为环状脓疱型银屑病急性加重,13岁时进展为泛发性脓疱型银屑病(GPP)。传统系统治疗(口服维A酸类、环孢素、甲氨蝶呤)在儿科因不良反应和长期后果不确定而存在争议。粒细胞单核细胞吸附疗法不良事件少,迅速控制了该儿科患者的GPP,有望成为DITRA儿科患者的合适替代治疗。
要点
- DITRA由IL36RN突变引起,典型表现为GPP,可呈年龄依赖性演变。
- 传统系统治疗在儿科GPP中因不良反应和长期后果不确定而存争议。
- 粒细胞单核细胞吸附疗法不良事件少,可迅速控制儿科DITRA的GPP。
核心结论
- 粒细胞单核细胞吸附疗法迅速控制了伴IL36RN突变儿科DITRA患者的GPP,可能成为合适替代治疗。
研究设计与样本
- 本文为单例儿科DITRA患者的病例报告,未报告样本量或研究设计细节。
主要发现
- 患者婴儿期表现为寻常型银屑病,后变为环状脓疱型银屑病伴急性加重,13岁时进展为GPP。
- 粒细胞单核细胞吸附疗法不良事件少,迅速控制了该儿科患者的GPP。
临床怎么用
- 对伴IL36RN突变的儿科DITRA/GPP患者,可考虑粒细胞单核细胞吸附疗法作为替代治疗。
局限性
- 证据仅来自单例病例报告,未报告长期疗效与安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with deficiency of interleukin-36 receptor antagonist (DITRA), due to mutation of IL36RN, exhibit psoriatic phenotypes, typically generalized pustular psoriasis (GPP). We report a paediatric patient with DITRA, whose cutaneous lesions varied from psoriasis vulgaris in infancy to annular pustular psoriasis with acute exacerbation to GPP at 13 years of age. Conventional systemic treatments for GPP, which include oral retinoids, ciclosporin and methotrexate, are controversial in paediatric cases, because of their adverse effects and uncertain long-term consequences. Granulocyte monocyte apheresis, a process associated with few adverse events, promptly controlled the GPP of our paediatric patient, and has potential as a suitable alternative treatment for paediatric patients with DITRA.
引用
- Koike Y, Okubo M, Kiyohara T, et al. Granulocyte and monocyte apheresis can control juvenile generalized pustular psoriasis with mutation of IL36RN. Br J Dermatol. 2017. PMID: 28369922. doi:10.1111/bjd.15509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。